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Abstract
Background: Multifamily group psychoeducation (MFG) has been shown to reduce relapse rates among
individuals with first-episode psychosis. However, given the cognitive demands associated with participating in this
intervention (e.g., learning and applying a structured problem-solving activity), the cognitive deficits that
accompany psychotic disorders may limit the ability of certain individuals to benefit from this intervention. Thus,
the goal of this study is to examine whether individuals with first-episode psychosis who participate simultaneously
in MFG and cognitive remediation–an intervention shown to improve cognitive functioning among individuals
with psychotic disorders–will be less likely to experience a relapse than individuals who participate in MFG alone.
Methods/Design: Forty individuals with first-episode psychosis and their caregiving relative will be recruited to
participate in this study. Individuals with first-episode psychosis will be randomized to one of two conditions: (i)
MFG with concurrent participation in cognitive remediation or (ii) MFG alone. The primary outcome for this study
is relapse of psychotic symptoms. We will also examine secondary outcomes among both individuals with first-
episode psychosis (i.e., social and vocational functioning, health-related quality of life, service utilization,
independent living status, and cognitive functioning) and their caregiving relatives (i.e., caregiver burden, anxiety,
and depression)
Discussion: Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., deficits in cognitive
functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits
derived from MFG.
Trial Registration: ClinicalTrials (NCT): NCT01196286
Background
There is growing evidence that the majority of the psy-
chosocial deterioration that accompanies psychotic dis-
orders occurs during the first few years of illness [1-3]
and that the prevention or delay of early deterioration
may be associated with a better course of illness [4-7].
One intervention which has been shown to be particu-
larly effective in the treatment of psychotic disorders is
family psychoeducation–an umbrella term for a group
of interventions that provide families with education
about psychotic disorders and strategies to improve pro-
blem-solving skills and communication within the family
[8]. To date, multiple studies have demonstrated that
the receipt of family psychoeducation is associated with
lower rates of relapse among individuals with psychotic
disorders [9,10] with individuals with first-episode psy-
chosis experiencing greater clinical benefits than indivi-
duals later in the course of a psychotic disorder [11,12].
One particular form of family psychoeducation which
has shown promise among individuals with first-episode
psychosis is multifamily group psychoeducation (MFG)
[11]. This intervention provides participants with infor-
mation about the course and treatment of psychotic dis-
orders and trains participants in the use of a structured
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the many challenges associated with living with a psy-
chotic disorder or caring for a relative with a psychotic
disorder. Among individuals with psychotic disorders,
participation in MFG is associated with reduced rates of
relapse [13,14], and the clinical benefit of this interven-
tion appears to be greater among individuals with first-
episode psychosis as opposed to individuals with a
chronic psychotic disorder [11]. The success of this
intervention among individuals with first-episode psy-
chosis has led to the incorporation of MFG within sev-
eral major international studies of first-episode
psychosis (e.g., OPUS [15] and TIPS [16]).
However, like all psychosocial interventions, some
individuals who participate in MFG will still experience
negative health outcomes. With regard to individuals
with first-episode psychosis, approximately 20% may
experience a symptomatic relapse and 50% may be hos-
pitalized over a two-year period despite participating in
family psychoeducation [11,13]. Thus, despite the clear
clinical benefits associated with participation in MFG,
there is still room for improvement with regard to the
clinical outcomes of individuals who participate in this
intervention.
One factor that may limit the benefit of psychosocial
treatments (e.g., MFG) for psychosis is the cognitive def-
icits that tend to accompany psychotic disorders [17,18].
Cognitive deficits in areas such as problem-solving abil-
ity, verbal memory, and attention are common in indivi-
duals with psychotic disorders [19,20] (including those
early in the course of a psychotic disorder [21,22]) and
have been recognized as a “rate-limiting” factor which
may hinder individuals’ ability to learn and execute new
skills [18,23]. In the context of MFG, these cognitive
deficits may hinder an individual’s ability to learn and
participate in the problem-solving activity which is the
hallmark of MFG. Addressing these cognitive deficits, in
particular those related to problem-solving, could poten-
tially facilitate greater participation and understanding
of the MFG problem-solving activity among individuals
with first-episode psychosis–thereby facilitating greater
clinical benefits associated with participation in this
intervention.
Recently, greater attention has been directed toward
the development of strategies to ameliorate the cognitive
deficits that accompany psychotic disorders. One strat-
egy which has been shown to be successful in this
endeavor is cognitive remediation (CR). This interven-
tion, which is recognized as a “best practice” in the
treatment of psychotic disorders [24,25], is typically
comprised of a series of repeated exercises delivered by
ac l i n i c i a no rv i aac o m p u t e rt h a ta r ed e s i g n e dt o
improve performance in cognitive functioning. A recent-
meta-analysis has shown that participation in cognitive
remediation programs is associated with improvements
in multiple domains of cognitive functioning, including
problem-solving ability [26]. The success of CR in
improving problem-solving skills (and other areas of
cognitive functioning) raises the possibility that indivi-
duals with first-episode psychosis who participate con-
currently in MFG and CR may be better able to learn
and apply the problem-solving activity completed during
MFG sessions. This, in turn, could lead to improve-
ments in outcomes experienced by these individuals.
Thus, the goal of this study is to examine whether
concurrent participation in MFG and CR is associated
with better outcomes among individuals with first-
episode psychosis than participation in MFG alone. We
hypothesize that relapse rates will be lower among indi-
viduals who participate in the MFG and CR condition
as opposed to MFG alone. However, recognizing that
the benefits of MFG and CR may not be limited to
relapse alone, we will also examine the benefits of these
interventions with regard to secondary outcome mea-
sures for both individuals with first-episode psychosis
and their caregiving relatives.
Methods/Design
This project was approved University of Arizona Human
Subjects Protection Program.
Participants
Sample Characteristics
Individuals with first-episode psychosis and their care-
giving relatives will be recruited from the Early Psycho-
sis Intervention Center (EPICENTER) at University
Physicians Hospital. EPICENTER is an outpatient treat-
ment program that provides evidence-based psychoso-
cial treatments for individuals experiencing their first
psychotic episode. Inclusion criteria for participants at
EPICENTER are (i) a diagnosis of an affective or schizo-
phrenia spectrum psychotic disorder as determined by
the Structured Clinical Interview for the DSM-IV (SCID
[27]), (ii) less than 5 years of frank psychotic symptoms
as determined by the Symptom Onset in Schizophrenia
inventory (SOS [28]), (iii) being between the ages of 18-
35, and (iv) willingness to receive treatment at EPICEN-
TER. The durational criteria for psychotic symptoms (<
5 years) is based on the operational definition of first-
episode psychosis outlined by Breitborde and colleagues
[29]. Individuals with first-episode psychosis are
excluded from EPICENTER if they meet criteria for sub-
stance-induced psychosis as determined by the SCID,
are unwilling or unable to provide informed consent, or
meet criteria for a diagnosis of mental retardation. Care-
giving relatives are defined as someone with whom the
individual with first-episode psychosis maintains consid-
erable face-to-face contact (≥ 10 hours per week).
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of the individual with first-episode psychosis. It is antici-
pated that some individuals with first-episode psychosis
will have more than one caregiving relative who wishes
to participate in the study; hence, we anticipate recruit-
ing ≈1.5 familial caregivers for each individual with first-
episode psychosis.
Given that the onset of psychosis typically occurs
between the ages of 15-35 [median ≈ 22-23 years] [30],
we expect that our cohort of individuals with recent-
onset psychosis will comprised largely of young adults.
As noted earlier, due to EPICENTER inclusion criteria,
no individuals younger than 18 years old will be
included in this study. As thep r e v a l e n c eo fp s y c h o t i c
disorders within the United States does not appear to
differ across racial or ethnic groups [31], we expect that
racial and ethnic distribution of individuals with first-
episode psychosis who participate in this study will be
consistent with the racial and ethnic distribution of Tuc-
son, Arizona. Per the 2000 U.S. Census data for Tucson,
Arizona, this would lead us to expect that the racial dis-
tribution of our sample will be 70% White, 4% African
American, 2% American Indian, 2% Asian American,
<1% Native Hawaiian or other Pacific Islander, 4% mul-
tiracial, and 17% other. With regard to ethnicity, we
expect that the overall sample will be comprised of 36%
Hispanic/Latino individuals and 64% non-Hispanic/
Latino individuals. We expect to find a similar ethnic
and racial breakdown among the family caregivers who
participate in this study.
First-episode psychosis studies have long reported
recruiting a preponderance of male subjects [32]. Thus,
we expect that our sample of individuals with first-
episode psychosis will be largely male (≈70%). Conversely,
studies of family caregivers of individuals with psychotic
disorders have historically recruited a preponderance of
female caregivers [33]. As such, we expect that our sample
of caregivers will be largely female (≈70%).
Number of Participants and Power Analysis
Current recommendations for a priori determination of
the number of subjects to include in a study suggest the
inclusion of sufficient subjects to maintain adequate sta-
tistical power to detect a clinically meaningful effect size
[34]. One such measure, Number Needed to Treat
(NNT) [35], has been identified as particularly useful in
conveying clinical significance and in guiding the design
of randomized clinical trials [36]. NNT provides an esti-
mate of the number of individuals who would need to
receive a treatment in order to prevent the occurrence
of one negative outcome. With regard to family psy-
choeducation, a recent meta-analysis found that the
NTT for this intervention was 8; (95% CI 6-18) [9]. This
suggests that this intervention would need to be pro-
vided to 8 individuals to prevent one relapse. Although
there is no established criteria for a clinically meaningful
reduction in NNT [36], for the current study we defined
a clinically meaningful benefit of the MFG and CR con-
dition as an NNT one-half the size of the NNT for
MFG along (i.e., an NNT for MFG and CR = 4). This
value (i.e., NNT = 4) falls outside of the 95% confidence
interval of the NNT for family psychoeducation alone as
reported in a past meta-analysis [9] and is consistent
with the NNT value use to determine a priori statistical
power for most randomized controlled trials of interven-
tions for mental illnesses [36]. Using these NNT values
and the pwr software package [37] developed for the R
statistical platform [38], we determined that 17 families
(i.e., individual with first-episode psychosis and caregiving
relative[s]) would need to be allocated to both the MFG-
CR and MFG alone conditions, respectively, to ensure
statistical power of 0.80 (i.e., total sample size = 34).
To protect against subject attrition, we will recruit an
additional 6 families (i.e., ≈20% of the total sample size),
bringing the total sample size to 40.
Randomization and Treatment Allocation
Treatment allocation for this study is depicted in Figure 1.
Upon enrollment in the project, individuals with first-epi-
sode psychosis will be randomized to either the MFG and
CR condition or the MFG alone condition. Randomization
will be completed using a block randomization procedure
with blocks of varying sizes.
Interventions
Multifamily Group Psychoeducation
Per the protocol outlined by McFarlane [11], the MFG
intervention involves three phases: (i) joining, a process
of engaging patients and their key family members, (ii) a
psychoeducational workshop, and (iii) multifamily pro-
blem-solving sessions. During the joining phase, family
members meet with the clinician who will lead the MFG
to discuss their ill relative’s clinical history, the family’s
experience and understanding of their ill relative’s ill-
ness, and family members’ concerns and questions with
regard to participating in a multifamily group. Concur-
rent to these sessions with the family, the individual
with first-episode psychosis will also complete three
individual sessions with the clinician to build rapport
and trust in the relationship between the clinician and
the individual with first-episode psychosis. Following the
completion of the joining phase, family members and
clinically stable patients participate in a day-long educa-
tional workshop on psychosis which provides an over-
view of the causes and prognosis of psychotic disorders,
current treatments for these disorders, and the ways in
which family members may be affected by severe mental
illness in the family. Family members are also presented
with guidelines for illness management as well as
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Following the completion of the psychoeducational
workshop, families and their ill relatives begin to partici-
pate in bi-weekly multifamily problem-solving sessions.
During the problem solving sessions, caregivers and ill
relatives identify challenges or problems occurring in
their lives and identify possible solutions to these pro-
blems through a structured problem-solving activity.
All individuals with first-episode psychosis will partici-
pate in the MFG intervention for twelve months. This
duration of treatment is consistent with recommenda-
tions from the Patient Outcomes Research Team
(PORT) convened by the Agency for Health Care Policy
and Research and the National Institute of Mental
Health [39,40]. Of note, unlike the traditional MFG
model, family groups in this study will be run using roll-
ing admissions with families graduating from the group
after twelve months of participation.
Cognitive Remediation
Individuals with first-episode psychosis who are rando-
mized to the MFG and CR condition will complete the
cognitive remediation program PSSCogRehab [41]. This
computerized cognitive remediation program provides
participants with training in 4 areas of cognitive func-
tioning: attention, visual-spatial abilities, memory, and
problem-solving abilities. Participants initially complete
simple tasks in each domain and, once mastered, gradu-
ally progress to more difficult tasks. Completion of the
training program occurs once subjects have mastered all
of the training tasks. This program has been frequently
used in past studies of cognitive remediation in psycho-
tic disorders [42-48], and more recently has been
applied specifically among individuals early in the course
of a psychotic illness [49,50]. This intervention has been
shown to promote improvements in problem-solving
among individuals with psychotic disorders [42], and
has been administered successfully with other concur-
rent psychosocial interventions [44].
Primary Outcome Measure
Relapse
Symptomatology among individuals with first-episode
psychosis will be assessed using the Positive and Nega-
tive Syndrome Scale (PANSS) [51] on a weekly basis
during their participation in the study. Based on partici-
pants’ scores on this measure, the occurrence of a
relapse will be determined using the criteria established
by Nuechterlein and colleagues [52]. Of note, although
the criteria outlined by Nuechterlein and colleagues
were designed for use with the Brief Psychiatric Rating
Scale (BPRS [53]), the specific items on the BPRS used
to determine the occurrence of a relapse using the
Nuechterlein criteria (i.e., hallucinations, unusual
thought content, and conceptual disorganization) are
also included in the PANSS (i.e., hallucinations, delu-
sions, and conceptual disorganization). These shared
Enrollment in 
EPICENTER Program
Enrollment in Current 
Study
(N = 40)
Randomized to MFG 
and CR
(n = 20)
Randomized to MFG 
Alone
(n = 20)
Figure 1 Patient Flow Diagram.
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sures and each item on BPRS has been shown to be
strongly correlated with its comparable item on the
P A N S S( w e i g h e dk a p p a so f0 . 6 5[ g o o d ]t o0 . 8 6[ e x c e l -
lent]) [54].
Secondary Outcome Measures
Recognizing that recovery from psychotic disorders
involves more than just a remission of psychotic symp-
toms [55], we will also explore the benefit of combining
MFG and CR on other outcomes among individuals
with first-episode psychosis. These will include social
and vocational functioning (Social Functioning Scale:
SFS [56]), everyday functioning (brief form of the UCSD
Performance-Based Skills Assessment: UPSA [57]),
health-related quality of life (RAND 36-Item Health Sur-
vey [58]), service utilization (Service Utilization and
Resources Form for Schizophrenia: SURF [59]), and
independent living status. Independent living status will
be assessed using the methodology outlined by Palmer
et al. [60]. Per this methodology, subjects’ living status
will be rated on a 4-point scale ranging from (1) ‘totally
dependent’ (i.e., living in a facility with 24-hour clinical
care) to (4) ‘independent’ (i.e., living alone or with a
partner who provides a level of support consistent in
typical cohabitation relationships). These measures will
be administered when subjects enroll in the study and
again after the completion of 12 months of MFG.
Additionally, to replicate findings linking participation
in CR to improved cognitive functioning among indivi-
duals with psychotic disorders [26], individuals with
first-episode will complete the consensus cognitive bat-
tery developed by the National Institute of Mental
Health’s Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) initia-
tive [61]. Of note, this battery does include a specific
assessment of problem-solving skills (i.e., the mazes
subtest from the Neuropsychological Assessment Battery
[62]). Participants in the MFG and CR condition will
complete the MATRICS battery three times over the
course of the study: (i) at enrollment; (ii) upon comple-
tion of CR intervention, and (iii) upon completion of 12
months of the MFG intervention. Individuals rando-
mized to the MFG alone condition will complete the
MATRICS battery three times over the course of the
study: (i) at enrollment, (ii) at 10 weeks, and (iii) upon
completion of 12 months of the MFG intervention
Caregiving relatives of individuals with psychotic dis-
orders have also been shown to experience a reduction
in caregiver burden and psychological distress (e.g.,
depression and anxiety) after participation in family psy-
choeducation [63,64]. Thus, we plan to conduct addi-
tional secondary analyses to examine whether caregivers
whose ill relatives are in the MFG and CR group
experience greater benefits in these areas as compared
to caregivers whose ill relatives are in the MFG alone
condition. Caregiver burden will be assessed using the
Burden Assessment Scale [BAS] [65], and depression
and anxiety will be assessed using the Beck Depression
Inventory [BDI] [66] and Beck Anxiety Inventory [BAI]
[67], respectively. These measures will be administered
upon enrollment to the study and after completion of
12 months of MFG.
Proposed Analyses
All analyses will be completed using an “intention-to-
treat” principle [68] such that data from all subjects will
be included in the analysis regardless of their level of
adherence to the interventions over the course of the
study.
The association between intervention condition (i.e.,
MFG and CR vs. MFG alone) and relapse will be exam-
ined using a chi-square. However, in situations in which
the requirements for this analysis are violated (e.g.,
expected value of any cell ≤ 5), Fisher’s exact probability
test [69] with the continuity correction proposed by
Overall [70] will be used instead.
Per the recommendations outlined by Vickers and Alt-
man [71], the association between intervention condi-
tion (i.e., MFG and CR vs. MFG alone) and continuous
secondary outcome measures (e.g., caregiver burden and
social functioning scores) will be examined using an
analysis of covariance with participants’ baseline scores
on the secondary outcome measure included as a cov-
ariate. With regard to the association between interven-
tion condition and categorical secondary outcome
measures (e.g., employed vs. unemployed), a chi-square
analysis will be used. However, in situations in which
the requirements for this analysis are violated, Fisher’s
exact probability test [69] with the continuity correction
proposed by Overall [70] will be used instead.
Discussion
Multifamily group psychoeducation is an evidence-based
and cost-effective treatment for psychotic disorders
[13,14,72]. However, like all psychosocial interventions,
certain individuals who participate in MFG will still go
on to experience negative health outcomes. Cognitive
remediation offers the possibility of ameliorating a speci-
fic deficit (i.e., a deficit in cognitive functioning) that
often accompanies psychotic symptoms and may restrict
the magnitude of the clinical benefits derived from
MFG.
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